Where most other types of medicines target proteins that cause or contribute to
disease after they're made, RNAi therapeutics prevent those proteins from being
made in the first place.
This approach is unlocking new possibilities for treating diseases and reducing the
frequency with which medicines need to be taken.
See our pipeline ›
As cutting-edge as this
sounds, research into the safety and effectiveness of RNAi therapeutics is extensive and is based on over
two decades of clinical trials.
The world’s first
RNAi therapeutic, and Alnylam’s first commercial medicine, was approved in 2018. Since then,
six other RNAi therapeutics have been approved in the United States and around the world.